Suchergebnisse - "Pinato, David J"

PubPharm (8)

1

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma : A network metanalysis of phase III trials

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Fulgenzi, C. | D'Alessio, A. | Airoldi, C. | +5

2

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

enthalten in: Journal of hepatology | 2022

von Scheiner, B. | Pomej, K. | Kirstein, M. | +38

CommentIn: J Hepatol. 2022 Apr;76(4):987-988. - PMID 34780876

3

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection : evidence from the OnCovid retrospective, multicentre registry study

enthalten in: The Lancet. Oncology | 2021

von Pinato, D. | Tabernero, J. | Bower, M. | +130

4

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Hashimoto, A. | Sarker, D. | Reebye, V. | +28

5

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

enthalten in: Journal of hepatology | 2021

von Gudd, C. | Au, L. | Triantafyllou, E. | +17

6

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer : A First-in-Human, Multicenter, Open-Label, Phase I Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Sarker, D. | Plummer, R. | Meyer, T. | +33

7

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

enthalten in: British journal of cancer | 2019

von Pinato, D. | Brown, M. | Trousil, S. | +6

8

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2014

von Blagden, S. | Omlin, A. | Olmin, A. | +17

ErratumIn: Clin Cancer Res. 2015 Feb 1;21(3):660 Olmin, Aurelius [corrected to Omlin, Aurelius]. - PMID 25646183

1
[1]